


Lymphoma

Jasmine Zain
2008

Lymphoma

- Malignancies arising from lymphoid tissue
- Hodgkin's Lymphoma/Disease
- Non-Hodgkin's Lymphoma




Statistical facts of 2007 in U.S

- 71,380 cases of NHL
- 8190 cases of H.D
- 5th most common cancer in males and females in the U.S
- Age adjusted incidence rose by 84% from 1974-2004
- Incidence increases by age

Clinical Features


- Enlarged lymph nodes
- Weight loss
- Fever
- Night sweats
- Itching



Mycosis Fungoides



Fig 1. Radiologically, this marginal zone B-cell lymphoma presented as (A) a dura-based mass with hyperdense signal on computed tomography scan; (B, C) homogeneous contrast enhancement and a dural tail sign, mimicking meningioma, on the T1-weighted magnetic resonance images (MRIs)



Tu, P.-h. et al. J Clin Oncol; 23:5718-5727 2005


Copyright © American Society of Clinical Oncology

JOURNAL OF CLINICAL ONCOLOGY

Diagnosis

- Tissue biopsy must be an adequate sample with intact tissue architecture
 - Excision biopsies
 - Core biopsy
- Fine needle aspirate acceptable only for recurrent disease or for hard to reach areas

Staging for H.D and Nodal NHL



Ann Arbor Staging System


Stage	Distribution of Disease
I	Involvement of a single lymph node region (I) or involvement of a single extralymphatic organ or site (I _E)
II	Involvement of two or more lymph node regions on the same side of the diaphragm alone (II) or with involvement of limited contiguous extralymphatic organ or tissue (II _E)
III	Involvement of lymph node regions on both sides of the diaphragm (III), which may include the spleen (III _s) and/or limited contiguous
IV	Multiple or disseminated foci of involvement of one or more extralymphatic organs or tissues with or without lymphatic involvement.

Diagnostic work up

- Biopsy and pathology review
- Complete blood counts
 - Anemia, pancytopenia
 - Lymphocytosis, abnormal cells on the smear
- Serum chemistries including LDH
- Staging scans
 - CT scans, PET scans, PET/CT
- Bone marrow biopsies

Hodgkin's Disease/Lymphoma

Characterized
by the
presence of
Reed
Sternberg cell




Classification of Hodgkin's Disease

Type	Percentage
• Nodular sclerosing	• 55
• Mixed cellularity	• 25
• Lymphocyte rich classical Hodgkin's disease	• 5
• Lymphocyte depleted	• 2
• Not classifiable	• 5

Hodgkin's Disease

- Curable in over 85% of cases
- Combination of chemotherapy and radiation therapy
- Monitor for secondary malignances


Survival rates in
H.D over time



Hodgkin's Lymphoma

- Different pattern of growth
- Response to therapy is different
- Curable in over 85% of cases with a combination of chemotherapy and radiation
- Monitor for secondary malignancies

Relative frequency of Non-Hodgkin's lymphomas



NHL

Clonal expansion of B, T or NK cells
Arise from lymph nodes or any
lymphoid tissue including brain, skin,
breast

Etiology of NHL


- Association with infection
 - EBV----- Burkitt's, NK-T, PTLD
 - HTLV-1---- HTLV1 associated ATL
 - Helico bacter pylori- Gastric MALTs
 - Borrelia Bergdorfi--- B cell lymphomas of skin
- Immunosuppression
 - Increased incidence in HIV infected
 - Organ transplantation
- Autoimmune states
 - Psoriasis
 - Schojern's syndrome
- Previous history of Lymphoma or H.D

Table 1.2: WHO Classification of NHL

B-cell	
Mature B-cell lymphomas	
Precursor B-cell lymphoma	Small lymphocytic lymphoma
	Lymphoplasmacytic lymphoma
	Splenic marginal zone lymphoma
	Hairy cell leukaemia
	Plasma cell neoplasms
	Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma)
	Nodal marginal zone B-cell lymphoma
	Follicular lymphoma (grades 1, 2, 3a and 3b)
	Diffuse follicle centre lymphoma
	Mantle cell lymphoma
	Diffuse large B-cell lymphoma
	Mediastinal (thymic) large B-cell lymphoma
	Intravascular large B-cell lymphoma
	Primary effusion lymphoma
	Burkitt lymphoma
B-cell proliferations of uncertain malignant potential	Lymphomatoid granulomatosis
	Post-transplant lymphoproliferative disorder, polymorphic
T-cell and NK-cell	
Precursor T- and NK-cell lymphomas	Precursor T lymphoblastic lymphoma
	Blastic NK-cell lymphoma
Mature T-cell and NK-cell lymphomas	T-cell prolymphocytic leukaemia
	T-cell large granular lymphocytic leukaemia
	Aggressive NK-cell leukaemia
	Adult T-cell lymphoma/leukaemia
	Extranodal NK-/T-cell lymphoma, nasal type
	Enteropathy-type T-cell lymphoma
	Hepatosplenic T-cell lymphoma
	Subcutaneous panniculitis-like T-cell lymphoma
	Mycosis fungoides
	Peripheral T-cell lymphoma unspecified
	Angioimmunoblastic T-cell lymphoma
Anaplastic large cell lymphoma	

Practical points

- B vs T vs NK-T cell lymphoma
- B NHL more common
 - Working formulation
 - Low grade (slow growing, poorly responsive to treatment)
 - Aggressive (fast growing, more likely to be cured with chemotherapy)
 - High grade (aggressive, life threatening behave like acute leukemias)




Prognosis of NHL

- Histological subtype determines clinical behavior and prognosis
- Accurate diagnosis
- Staging
- Age
- LDH
- Performance status
- Other prognostic factors unique to histological subtype

Immunophenotyping

- B cell malignancies—CD19, CD20, kappa/ lambda light chain restriction
- Tcell malignancies-----CD3, CD4, CD5, CD4, CD8, Tcell gene rearrangements
- NK-T cell---- CD56, CD16 usually EBV positive

Diffuse large B cell lymphoma vs Follicular lymphoma





Treatment

- Tailored to the type of NHL
- B cells vs T cells
 - Different therapeutic approaches
- Low grade vs aggressive or high grade
 - Immediate treatment vs wait and watch
- General condition of the patient
- Site of origin
 - Skin
 - brain



Chemotherapy

- Combination chemotherapy has shown the best results for both HD and NHL
- Most active drugs are
 - Alkylating agents
 - Anthracyclins
 - Topoisomerase I and II inhibitors
 - Steroids


Rituximab anti - CD20



Alemetuzemab (Campath) Anti- CD52



Denileukin Diftitox Ontak



Radiation therapy

- External beam radiation
- Radioimmunotherapy
 - Ibritumomab Tiuxetan (Zevalin)
 - I-131 Tositumomab

Targeted therapies

- HDAC inhibitors
- Hypomethylating agents
- Syk inhibitors
- M-TOR inhibitors

Principles of Underlining Cure by BMT

- | | |
|---------------|--|
| 1. AUTOLOGOUS | <p>Ablation of host normal hematopoiesis and malignancy (hematologic and solid tumor)</p> <p>Re-establishment of host hematopoiesis</p> <p>Host immune reconstitution (stem cell derived)</p> |
| 2. ALLOGENEIC | <p>Ablation of host hematopoiesis, normal and malignant</p> <p>Re-establishment of donor hematopoiesis</p> <p>Donor immune reconstitution (stem cell derived)</p> <p>Donor anti-tumor effect (GVL)</p> |

